# TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

> **NCT07223528** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Chan, Stephen, MD, PhD** · enrollment: 28 (estimated)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Telaglenastat

## Key facts

- **NCT ID:** NCT07223528
- **Lead sponsor:** Chan, Stephen, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223528, "TEPH: Telaglenastat Efficacy in Pulmonary Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07223528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*